Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Research by N. Mottet and colleagues in cancer vaccines provides new insights
May 27th, 2008
According to recent research from France, "The hormone-refractory status is defined in a confirmed castrated man (who stopped any antiandrogen 6 wk earlier) by three consecutive prostate-specific antigen (PSA) increases above the nadir, reaching at least more than 50% of the nadir. It is standard of care to continue androgen-deprivation therapy (ADT) at this time." "Two randomized phase 3 trials have demonstrated a survival benefit of 2 mo using a 3-wk docetaxel regimen, with a follow up of more than 50 mo. The decision for an immediate or a symptom-triggered-delayed chemotherapy must be tailored on the basis of prognostic factors such as a high PSA level, a short PSA...
Source: Cancer Weekly (2008-05-27)
|
